Nervgen Pharma (NGEN) Total Liabilities (2024 - 2026)

Nervgen Pharma (NGEN) has reported Total Liabilities for 3 consecutive years, with $65.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities changed N/A year-over-year to $65.2 million in Q2 2026; TTM through Jun 2026 was $65.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $16.6 million, up 34.76% from the prior year.
• Total Liabilities was $65.2 million for Q2 2026 at Nervgen Pharma, up from $15.1 million in the prior quarter.
• Over five years, Total Liabilities peaked at $65.2 million in Q2 2026 and troughed at $12.1 million in Q4 2024.
• A 3-year average of $27.3 million and a median of $15.9 million in 2025 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 37.49% in 2025, down 37.49% in 2025.
• Over 3 years, Total Liabilities stood at $12.1 million in 2024, then soared by 37.49% to $16.6 million in 2025, then jumped by 291.76% to $65.2 million in 2026.
• The last three Total Liabilities figures came in at $65.2 million (Q2 2026), $15.1 million (Q1 2026), and $16.6 million (Q4 2025), per Business Quant data.